Inclusion Criteria:

- Metastatic pancreatic carcinoma (excluding pancreatic endocrine tumors)

- Only patients with measurable disease

- ECOG performance status < or equal to 1

- Life expectancy >12 weeks

- Signed informed consent

- Failed or intolerance to first-line therapy for metastatic disease with a
gemcitabine-containing regimen. Patients may have received adjuvant therapy in
addition to one prior regimen for metastatic disease.

- >4 weeks must have elapsed from the completion of previous chemotherapy and patients
must have recovered from any related toxicities

- >4 weeks must have elapsed from the participation in any investigational drug study

- Laboratory values:

- ANC > 1500/mm3;

- Hemoglobin > 9.0 gm/dl;

- Platelets > 100,000/mm3;

- SGOT <2.5 X upper limit of normal; or <5 X upper limit of normal if evidence of
liver metastases; Alkaline phosphatase < 2.5 X upper limit of normal; or < 5 X
upper limit of normal if evidence of liver metastases; Total bilirubin < 1.5 X
upper limit of normal; Creatinine clearance > 50 cc/min (by Cockroft - Gault or
as determined from a 24-hour urine collection).

Exclusion Criteria:

- Prior therapy with capecitabine or epidermal growth factor receptor (EGFR) inhibitors

- More than one prior chemotherapy treatment regimen for metastatic disease

- Clinically apparent central nervous system (CNS) metastases or carcinomatous
meningitis

- Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic
coronary artery disease and cardiac arrhythmias not well controlled with medication
or heart attack within the last 12 months).

- Major surgery within 4 weeks of the start of study treatment, without complete
recovery.

- Evidence of CNS metastases (unless CNS metastases have been stable for > 3 months) or
history of uncontrolled seizures, central nervous system disorders

- Uncontrolled serious medical or psychiatric illness

- Women must not be pregnant or lactating

- Concurrent radiation therapy

- Other active malignancy

- Inability to swallow tablets

- Patients lacking physical integrity of the upper gastrointestinal tract or who have
malabsorption syndrome

- Prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity
to 5-fluorouracil